Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Publications

Shittu I, Oguzie JU, Hernández-Vidal G, Moreno-Degollado G, Silva DB, Marushchak LV, Trujillo-Vargas CM, Lednicky JA, Gray GC

Novel Rodent Coronavirus-like Virus Detected Among Beef Cattle with Respiratory Disease in Mexico.

Viruses. 2025;17(3)

İlhan N, Doğan A, Erölmez HN, Atalah F, Baş S, Yasar S, Odabaş H, Gümüş M

The Incidence and Clinical Characteristics of Interstitial Lung Disease Associated with CDK4/6 Inhibitors in Breast Cancer Patients: A Retrospective Multicenter Study.

Medicina (Kaunas, Lithuania). 2025;61(3)

Schlam I, Giordano A, Tolaney SM

Interstitial lung disease and CDK4/6 inhibitors in the treatment of breast cancer.

Expert opinion on drug safety. 2023;22(12):1149-1156

Jazieh KA, Budd GT, Dalpiaz N, Abraham J

Can CDK4/6 inhibitors cause fatal lung injury?

Expert review of anticancer therapy. 2019;19(11):917-919